CLINICAL TRIALS PROFILE FOR INCB054707
✉ Email this page to a colleague
Clinical Trials for INCB054707
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03569371 ↗ | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Completed | Incyte Corporation | Phase 2 | The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS). |
NCT03607487 ↗ | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Completed | Incyte Corporation | Phase 2 | The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa. |
NCT04476043 ↗ | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Active, not recruiting | Incyte Corporation | Phase 2 | To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period. |
NCT04818346 ↗ | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo | Recruiting | Incyte Corporation | Phase 2 | The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo. |
NCT05061693 ↗ | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | Recruiting | Incyte Corporation | Phase 2 | The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period. |
NCT05068466 ↗ | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 | Not yet recruiting | Incyte Biosciences Japan GK | Phase 1 | This is a single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded, Phase 1 study designed to evaluate the safety, tolerability, and PK of escalating oral doses of INCB054707 in healthy male Japanese participants. Participants in each cohort will be divided into placebo or INCB054707 by a 3:1 INCB054707:placebo random assignment. |
NCT05620823 ↗ | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Not yet recruiting | Incyte Corporation | Phase 3 | The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for INCB054707
Condition Name
Clinical Trial Locations for INCB054707
Trials by Country
Clinical Trial Progress for INCB054707
Clinical Trial Phase
Clinical Trial Sponsors for INCB054707
Sponsor Name